This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: H18.5 | Special Copayment Reduction: V307 (5 years) |
| B. Synonyms | Fuchs dystrophy, corneal endothelial dystrophy, Fuchs endothelial dystrophy |
| C. Adult onset | Likelihood of first onset in adulthood very high — symptoms usually appear in the 50s–60s; preclinical findings (guttae) may be observed in the 30s–40s |
| 1. History | Ernst Fuchs (1902) first described the corneal abnormality; Vogt (1921) established the guttae finding; in 2006, the advent of DSEK and DMEK shifted the surgical paradigm |
| 2. Causes | Decreased number and function of corneal endothelial cells causes corneal stromal edema; complex genetic causes including TCF4 CTG18.1 repeat expansion and SLC4A11 and ZEB1 variants |
| 3. Genetics | TCF4 CTG18.1 repeat expansion (≥70% of patients), SLC4A11, ZEB1, LOXHD1, AGBL1; autosomal dominant or sporadic |
| 4. Epidemiology | Prevalence 4–7% in Western populations; the single largest indication for corneal transplantation in the US; female:male = 2.5–3:1; prevalence rises sharply after the 50s |
| 5. Pathophysiology | TCF4 CUG repeat RNA toxicity (MBNL sequestration), oxidative stress, TGF-beta hyperactivity → Descemet membrane thickening, guttae formation, endothelial cell loss |
| 6. Symptoms | Reduced vision in the morning (diurnal variation), glare, blurred vision; with progression, persistent all-day vision loss and pain from bullae |
| 7. Signs | Slit lamp: Descemet membrane guttae (beaten-metal pattern); specular microscopy: reduced ECD and pleomorphism; progression: corneal edema, bullous keratopathy |
| 8. Screening | Slit lamp retroillumination, specular microscopy (ECD, CV, 6A%), corneal thickness measurement (pachymetry), anterior segment OCT; regular examinations for high-risk families |
| 9. Diagnosis | Slit lamp guttae + specular microscopy + anterior segment OCT + corneal thickness; confirmation by TCF4 genetic testing; use of Krachmer grading |
| 10. Treatment | Early: hypertonic NaCl 5% eye drops; surgery: DMEK (gold standard)/DSAEK; emerging: CRISPR gene therapy, DT-168 (ASO), cultured endothelial cell transplantation |
| 11. Prognosis | DMEK 10-year graft survival about 85%; median time to BCVA>=6/12 7.8 months; rejection rate <1%; if left untreated without surgery, risk of irreversible blindness |
| 12. Prevention | Genetic counseling, family screening examinations, UV protection, ECD assessment mandatory before intraocular surgery, no smoking, intraocular pressure control |
| 13. References | 10 references listed with PMID/DOI (below) |
Fuchs endothelial corneal dystrophy (FECD) was first described in 1902 by the Austrian ophthalmologist Ernst Fuchs. Fuchs defined the clinical entity of this disease by reporting 13 cases of vision loss accompanied by characteristic changes on the corneal endothelial side. Then, in 1921, Alfred Vogt established the diagnostic basis by using biomicroscopy to systematically describe guttae, punctate excrescences on the posterior surface of Descemet membrane. From the mid-20th century, penetrating keratoplasty (PK) was the only surgical treatment, but the development of Descemet stripping endothelial keratoplasty (DSEK) in 2004 and Descemet membrane endothelial keratoplasty (DMEK) in 2006 opened the era of endothelial keratoplasty, which selectively replaces only the endothelial cells. By minimizing graft thickness to 10–15 μm, DMEK surpasses PK in speed of visual recovery, refractive stability, and rejection rate, and has now become established as the gold standard surgery.
On the molecular biological side, SLC4A11 gene variants were first reported in 2006, and in 2015 a landmark finding was published that CTG trinucleotide repeat expansion within intron 2 of TCF4 is found in more than 70% of patients with FECD. This established FECD as a new member of the RNA repeat expansion diseases with RNA toxicity (CUG repeat toxicity) as the core mechanism, and mechanistic knowledge accumulated from research on myotonic dystrophy (DM1) began to be applied directly to FECD treatment strategies. In the 2020s, strategies to block RNA toxicity using CRISPR/Cas9-based gene correction and antisense oligonucleotides (ASOs) reached the stage of clinical entry.
The underlying cause of FECD is progressive loss and dysfunction of corneal endothelial cells. Normal corneal endothelial cells are distributed at a density of about 2,000–3,000 cells/mm² and maintain the water balance of the corneal stroma through active pump function by Na⁺/K⁺-ATPase and carbonic anhydrase. Corneal endothelial cells have extremely limited capacity to divide, so as cell loss accumulates, the remaining cells expand their area to fill the gaps, but when cell density eventually falls below a critical threshold, pump function reaches its limit and corneal edema develops.
The causes of cell damage are multifactorial. CTG repeat expansion within intron 2 of the TCF4 gene (CTG18.1 locus) is the most common molecular cause; the toxic CUG repeat RNA forms foci in the nuclei of endothelial cells, sequestering MBNL1/2 proteins and causing widespread RNA splicing abnormalities. SLC4A11 gene variants cause reduced NH₃·H₂O transport function of corneal endothelial cells and reduced mitochondrial membrane potential. ZEB1 variants promote epithelial-mesenchymal transition (EMT) of endothelial cells, and LOXHD1, AGBL1, LAMC1, and COL8A2 variants also contribute through abnormalities of structural proteins. Among non-genetic factors, long-term UV exposure, accumulated oxidative stress, TGF-β1/β2 hyperactivity, and reduced estrogen accelerate endothelial cell aging.
FECD is genetically highly heterogeneous, and at least 9 genetic loci (FECD1–9) have been identified. The main genes are as follows.
The inheritance pattern is predominantly autosomal dominant but with incomplete penetrance, and about half of cases occur sporadically without a family history. This is thought to be due to somatic mosaicism of the TCF4 repeat expansion, de novo mutations, or non-genetic contributions. For diagnostic genetic testing, TCF4 CTG18.1 repeat analysis (fragment analysis or long-read sequencing) has the highest diagnostic yield, and if negative, panel analysis including SLC4A11 and ZEB1 is added.
FECD has a relatively high prevalence even among rare diseases. In Western populations, the prevalence based on slit lamp guttae findings is about 4–7%, and progressive FECD causing clinically significant symptoms is estimated at about 0.1–1%. In the United States, more than half of the approximately 40,000 corneal transplants performed each year are due to FECD, making it the leading indication for corneal transplantation as a single disease. In Europe as well, FECD is reported as the most common indication for corneal transplantation.
The sex distribution shows marked female predominance, with a female:male ratio of about 2.5–3:1. Proposed reasons for the higher prevalence in women include loss of the endothelial protective effect of estrogen (after menopause), increased TGF-β activity, and sex-modifying effects on genetic predisposition. Age of onset is in the 30s–40s for the early-onset form (FECD1, COL8A2 variants), whereas the late-onset form (FECD6, TCF4) is in the 50s–70s and much more common. It is also reported outside Western countries, in Asia and Latin America, but with somewhat lower prevalence. In Korea, exact figures based on rare disease Special Copayment Reduction (V307) registrants are of limited public availability, but it is recognized as one of the top 1–2 indications for corneal transplantation.
The pathogenesis of FECD is understood at the molecular level through three major pathways.
When the CTG repeat within intron 2 of the TCF4 gene is expanded, the CUG repeat RNA produced during transcription forms nuclear foci that sequester the MBNL1/2 splicing regulatory proteins. Loss of MBNL function causes widespread alternative splicing abnormalities similar to myotonic dystrophy (DM1), disrupting the post-transcriptional regulation of hundreds of genes involved in cell survival and death regulation, the cytoskeleton, cell adhesion, ion channel expression, and more. This mechanism means that FECD belongs to the category of RNA repeat expansion diseases (nucleotide repeat expansion disorder) and is the molecular target of ASO and CRISPR treatment strategies.
Loss of SLC4A11 protein function causes abnormal NH₃·H₂O transport and reduced mitochondrial membrane potential. Excess production of reactive oxygen species (ROS) promotes premature senescence, DNA damage, and apoptosis of endothelial cells. mtDNA damage and replication abnormalities are consistently observed in endothelial cells in advanced FECD. Environmental factors such as UV exposure, smoking, and metabolic abnormalities aggravate this oxidative damage pathway.
TGF-β1/β2 overexpression induces epithelial-mesenchymal transition (EMT) of endothelial cells, converting the cells to a fibroblast phenotype. ZEB1 variants directly accelerate this EMT process. An abnormal posterior collagenous layer (APNL) 2–5 times thicker than normal accumulates in Descemet membrane, and guttae composed of aggregates of collagen IV, fibronectin, and laminin form as protrusions on the posterior surface of the endothelium. Progressive thickening of Descemet membrane impairs nutrient supply from the aqueous humor, forming a vicious cycle that accelerates endothelial cell loss.
The symptoms of FECD appear gradually according to the disease stage and are often absent in the early stage.
Slit lamp biomicroscopy is central to the diagnosis of FECD.
Systematic screening of clinically high-risk groups is recommended for FECD. High-risk groups include those with a positive family history, women aged 40 or older, and patients scheduled for intraocular surgery (such as cataract surgery).
The diagnosis of FECD is based on clinical findings and confirmed with ancillary tests. There is no single gold-standard diagnostic criterion, but the diagnosis is made by a combination of the following elements.
In vivo confocal microscopy (IVCM) allows observation of the three-dimensional morphology of guttae and endothelial cell nuclei. Anterior chamber angle OCT checks for associated angle abnormalities. Gene panel testing (including TCF4, SLC4A11, ZEB1, LOXHD1, AGBL1) identifies the molecular cause. When necessary, examination of first-degree relatives is recommended together with a family history review.
The prognosis of patients with FECD who receive appropriate surgical treatment is generally good. In 10-year follow-up studies, graft survival was about 85% for DMEK and about 79% for DSAEK, significantly higher than for PK. Rates of achieving best-corrected visual acuity (BCVA) ≥6/12 were 91% for DMEK, 82% for DSAEK, and 68% for PK. Rejection rates are <1% for DMEK, 5–10% for DSAEK, and 15–20% for PK.
Major postoperative complications include graft detachment (about 10–20% with DMEK; most successfully rebubbled), primary graft failure (<1%), rejection, and elevated intraocular pressure (secondary ocular hypertension due to steroid eye drops). A larger TCF4 repeat number tends to be associated with earlier onset and faster progression, but expressivity varies widely between individuals. Endothelial cell loss can accelerate after intraocular surgery, so ECD assessment before cataract surgery and use of the optimal technique are important for prognosis. If left untreated, chronic pain from bullous keratopathy and severe visual impairment may progress irreversibly.
Because FECD has a strong genetic predisposition, complete primary prevention is currently not possible. However, the following measures are clinically recommended to delay progression and prevent complications.